IOncology

At the recent 7th Tianfu Oncology Conference, Professor Jie Wang from the Cancer Hospital, Chinese Academy of Medical Sciences, delivered a keynote presentation titled “Integrative Strategies in Lung Cancer: Targeted Therapy, Immunotherapy, and ADC Management.”

With advances in technology and growing clinical experience, China’s development of antibody-drug conjugates (ADCs) has evolved from following international trends to driving innovation independently. A recent example is the phase I clinical trial of YL201—the world’s first B7-H3-targeted ADC for advanced solid tumors—led by Professors Li Zhang and Hongyun Zhao from Sun Yat-sen University Cancer Center. The results were published in Nature Medicine, one of the most respected medical journals worldwide, marking a new step in global recognition for domestically developed therapies.

In a recent ESSO Research Academy survey led by Carmela Caballero and co-authored by Prof. Isabel T. Rubio, Prof. Evandro de Azambuja, and Prof. Stuart A. McIntosh, both clinicians and…

A new study led by Dr. Rafael Nambo Venegas and colleagues, published in Metabolomics (Feb 2025), presents a high-accuracy predictive model for forecasting response to neoadjuvant therapy in breast cancer…

In a recent study published in December 2024, Professor Isabel Rubio and her colleagues critically examined the limitations of current age-based breast cancer screening programs, which remain standard in most…

On April 10, 2025, a research team led by Professor Li Zhang and Professor Wenfeng Fang from Sun Yat-sen University Cancer Center published a significant study in the world-renowned journal…

In this special episode of Mok Talk, Professor Tony Mok (The Chinese University of Hong Kong) sits down with three rising oncology experts Professor Yang Xia (Zhejiang University), Professor Wenhua…

Join us for an exclusive conversation between Prof. Yansong Lin of Peking Union Medical College Hospital and Prof. Lori Wirth at Massachusetts General Hospital. In this special academic exchange, the…

The 2025 CSCO Guidelines Conference, co-hosted by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Xisike Clinical Oncology Research Foundation, was successfully held in Jinan, April 18–19, 2025. Leading experts from across the country gathered once again to exchange cutting-edge research, discuss clinical hot topics, and witness the release of updated CSCO guidelines. Oncology Frontier had the honor of interviewing the conference chair, CSCO Council President, and Academician Jinming Yu of Shandong Cancer Hospital, who shared insights into proton therapy, combined radiotherapy and immunotherapy, and CSCO’s path toward deeper international collaboration.